References
- Almond P S, Matas A J, Gillingham K, , et al Predictors of chronic rejection in renal transplant recipients. Transplant. Proc. 1993;25(1 Pt 2):936. [PUBMED], [INFOTRIEVE], [CSA]
- Pirsch J D, Gange S, D'Alessandro A M, , et al Determinants of graft survival after renal transplantation. Transplantation. 1996;61(11):1581-1586. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cole E, Naimark D, Aprile M, , et al An analysis of predictors of long-term cadaveric renal allograft survival. Clin. Transplant. 1995;9(4):282-288. [PUBMED], [INFOTRIEVE], [CSA]
- Carpenter C B.Long-term failure of renal transplants: adding insult to injury. Kidney Int. 1995;50(suppl):S40-S44. [CSA]
- Conesa E L, Valero F, Nadal J C, , et al N-acetyl-l-cysteine improves renal medullary hypoperfusion in acute renal failure. Am. J. Physiol., Regul. Integr. Comp Physiol. 2001;281(3):R730-R737. [CSA]
- Goode H F, Webster N R, Howdle P D, , et al Reperfusion injury, antioxidants and hemodynamics during orthotopic liver transplantation. Hepatology. 1994;19(2):354-359. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Carini R, Albano E Recent insights on the mechanisms of liver preconditioning. Gastroenterology. 2003;125(5):1480-1491. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bulkley G B.Free radical mediated reperfusion injury: a selective review. Br. J. Cancer. 1987;55: 66-73. [CSA]
- Osterrieder W, Hick M In vitro pharmacologic profile of Ro 40-5967, a novel Ca21 channel blocker with potent vasodilatory but weak inotropic action. J. Cardiovasc. Pharmacol. 1989;13(5):754-759. [PUBMED], [INFOTRIEVE], [CSA]
- Rutledge A, Triggle D J.The binding interactions of Ro 40-5967 at the L-type Ca2 + channel in cardiac tissue. Eur. J. Pharmacol. 1995;280(2):155-158. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mehrke G, Zong X G, Flockerzi V, Hofmann F The Ca2 + channel blocker Ro 40-5967 blocks differently T-type and L-type Ca2 + channels. J. Pharmacol. Exp. Ther. 1994;271(3):1483-1488. [PUBMED], [INFOTRIEVE], [CSA]
- Mishra S K, Hermsmeyer K Selective inhibition of T type Ca2 + channels by Ro 40-5967. Circ. Res. 1994;75(1):144-148. [PUBMED], [INFOTRIEVE], [CSA]
- Honda M, Hayashi K, Matsuda H, , et al Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J. Hypertens. 2001;19(11):2031-2037. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nakamura Y, Ono H, Frohlich E D.Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension. 1999;34(2):273-278. [PUBMED], [INFOTRIEVE], [CSA]
- Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension. 2001;38(3):343-347. [PUBMED], [INFOTRIEVE], [CSA]
- Bradford M M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72(7):248-254. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wasowicz W, Neve J, Peretz A Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storge. Clin. Chem. 1993;39(12):2522-2526. [PUBMED], [INFOTRIEVE], [CSA]
- Lowry O H, Rosebrough N J, Faar A L, Randall R J.Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951;193(1):265-275. [PUBMED], [INFOTRIEVE], [CSA]
- Molitoris B A.The potential role of ischemia in renal disease progression. Kidney Int. 1992;36(suppl):S21-S25. [CSA]
- Paller M S.The cell biology of reperfusion injury in the kidney. J. Investig. Med. 1994;42(4):632-639. [PUBMED], [INFOTRIEVE], [CSA]
- Weight S C, Bell P R, Nicholson M L.Renal ischaemia-reperfusion injury. Br. J. Surg. 1996;83(2):162-170. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Thadhani R, Pascual M, Bonventre J V.Acute renal failure. N. Engl. J. Med. 1996;334(22):1448-1460. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Padanilam B J.Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am. J. Physiol. 2003;284(4):F608-F627. [CSA]
- Heinzelmann M, Mercer-Jones M A, Passmore J C.Neutrophil and renal failure. Am. J. Kidney Dis. 1999;34(2):384-399. [PUBMED], [INFOTRIEVE], [CSA]
- Loutzenhiser R D, Epstein M Calcium antagonists and the kidney. Am. J. Hypertens. 1989(2):154S-161S. [CSA]
- Kimura K, Tojo A, Hirata Y, Hayakawa H, Goto A, Omata M Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles. Blood Press. 1994;5(suppl):71-74. [CSA]
- Osterrieder W, Holck M In vitro pharmacological profile of Ro 40-5967, a novel Ca2 + channel blocker with potent vasodilator but weak inotropic action. J. Cardiovasc. Pharmacol. 1989;13(5):754-759. [PUBMED], [INFOTRIEVE], [CSA]
- Avdonin P V, Buhler F R, Tkachuk V A.Ca2 + -agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967). Membr. Cell Biol. 2000;13(5):645-655. [PUBMED], [INFOTRIEVE], [CSA]
- Cribbs L L, Lee J H, Yang J, , et al Cloning and characterization of α1H from human heart, a member of the T-type Ca2 + channel gene family. Circ. Res. 1998;83(1):103-109. [PUBMED], [INFOTRIEVE], [CSA]
- Hackenthal E, Paul M, Ganten D, Taugner R Morphology, physiology and molecular biology of renin secretion. Physiol. Rev. 1990;70(4):1067-1116. [PUBMED], [INFOTRIEVE], [CSA]
- Opie L H.Reperfusion injury and its pharmacological modification. Circulation. 1989;80(4):1049-1061. [PUBMED], [INFOTRIEVE], [CSA]
- Miller T W, Tormey J M.Subcellular Ca2 + pools of ischaemic and reperfused myocardium characterised by electron probe. Cardiovasc. Res. 1995;29(1):85-94. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Halestrap A P, Kerr P M, Javadov S, Woodfield K Y.Elucidating the molecular mechanism of permeability transition pore and its role in reperfusion injury of the heart. Biochim. Biophys. Acta. 1998;1366(1–2):79-94. [PUBMED], [INFOTRIEVE], [CSA]
- Garcia J J, Reiter R J, Guerrero J M, , et al Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett. 1997;408(3):297-300. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Trimarchi H, Mongitore M R, Baglione P, , et al N-acetylcisteine reduces malondialdehyde levels in chronic hemodialysis patients—a pilot study. Clin. Nephrol. 2003;59(6):441-446. [PUBMED], [INFOTRIEVE], [CSA]
- Freudenthaler S M, Schreeb K H, Wiese A, Pilz J, Gleiter C H.Influence of controlled hypoxia and radical scavenging agents on erythropoietin and malondialdehyde concentration in humans. Acta Physiol. Scand. 2002;174(3):231-235. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Agarwal R Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am. J. Physiol. 2003;284(4):F863-F869. [CSA]